Document:

Exhibit 10.3

 

AMENDING
AGREEMENT

 

This
Amending Agreement (the “Agreement”), effective as of April 8, 2021 (the “Effective Date”),
is by and between VBI VACCINES INC., a company organized under the laws of the Province of British Columbia, Canada (“VBI”),
and having a principal place of business at 310 Hunt Club Road, Suite 201, Ottawa ON K1V 1C1, and Brii Biosciences Limited,
an exempted company organized under the laws of the Cayman Islands (“Brii Bio”), having its registered office
at Vistra (Cayman) Limited, PO Box 3119, Grand Pavilion Hibiscus Way, 802 West Bay Road Grand Cayman KYI- 1205. VBI and Brii Bio
are sometimes referred to as a “Party” and are collectively referred to as the “Parties”.
Terms having capital letters which are not defined herein shall have the meanings given thereto in the Collaboration Agreement
(as defined below).

 

WHEREAS,
VBI and Brii Bio are parties to a certain Collaboration and License Agreement dated December 4, 2018 (the “Collaboration
Agreement”);

 

WHEREAS,
pursuant to the Collaboration Agreement, VBI and Brii Bio agreed that Brii Bio would conduct a Collaboration Clinical Trial in
the Licensed Territory in order to support an application for Marketing Approval in the Licensed Territory;

 

WHEREAS,
following execution of the Collaboration Agreement, the Parties decided that it would be preferable to expand the Collaboration
Clinical Trial to countries outside the Licensed Territory for the purpose of supporting the application for Marketing Approval
in the Licensed Territory;

 

AND
WHEREAS, the Parties wish to amend the Collaboration Agreement in accordance with Section 17.4 thereof in order to set out
their intention regarding expansion of the Collaboration Clinical Trial on the terms and conditions set out in this Agreement;

 

NOW
THEREFORE, in consideration of the mutual covenants contained herein, the Parties agree as follows:

 

1.
Amendment to Article 1 - Definitions.
Effective as of the December 4, 2018, Article 1 of the Collaboration
Agreement shall be amended as follows:

 

	 	(a)	Section
    1.18 shall be deleted in its entirety and
    replaced with the following:

 

1.18
“Collaboration Clinical Trial” shall mean the Phase II Clinical Trial, to be conducted in accordance with
the Development Plan in order to support an application for Marketing Approval in the Licensed Territory for the purpose of comparing
VBI-2601 and a Novel Composition across multiple cohorts and dosing regimens.

 

(b)
Section 1.93 shall be deleted in its entirety
and replace with the following

 

1.93
“VBI Know-How” shall mean all Know-How owned or Controlled by VBI (which includes Know-How of its Affiliates)
as of the Effective Date or during the Term that is necessary or useful to research, develop, make, have made, distribute, use,
sell, offer for sale, have sold, import, export and otherwise commercialize the Licensed Compounds or Licensed Products. For the
avoidance of doubt, the “VBI Know-How” shall not include Joint Know-How.

 

    	1

    	 

    

 

2.
Amendment to Section 3.1 (b). Effective
as of December 4, 2018, Section 3.1(b) of the Collaboration Agreement shall be deleted
in its entirety and replaced with the following:

 

(b)
perform, or have performed, (i) studies (including Clinical Trials) and (ii) regulatory and other activities, each of (i)
and (ii) as may be required to obtain and maintain Marketing Approval of the Licensed
Products in the Licensed Territory; and

 

3.
Amendment to Article 5. Effective
as of December 4, 2018, Article 5 shall be amended as follows:

 

	 	(a)	Section
    5.1(a)(v) shall be deleted in its entirety and replaced with the following:

 

	 	(v)	technology
    transfer of immune-monitoring assays to support clinical development in support of an application for Marketing Approval in
    the Licensed Territory;

 

	 	(b)	Section
    5.1(b) shall be deleted in its entirely and replace with the following:

 

(a)
Review and Amendment of the Development
Plan. From time to time, and no less than once per calendar
year, the Joint Steering Committee shall review the Development Plan and determine if any amendments or additions are required
in order to advance the objective of obtaining Marketing Approval for a Licensed Product in the Licensed Territory. Any modifications
or amendments to the Development Plan shall become effective when reduced to writing and signed by both Parties or when included
in minutes of the JSC which are approved by both Parties.

 

	 	(b)	Section
    5.3(b) shall be deleted in its entirety and
    replaced with the following:

 

(b)
Post-Development Plan Costs. With the exception of costs related to Global Clinical
Trials (as applicable), all Clinical Trials conducted for the purpose of supporting an application for Marketing Approval in the
Licensed Territory following the conclusion of the Development Plan shall be borne by Brii Bio.

 

    	2

    	 

    

 

4.
Amendment to Article 7.
Effective as of December 4, 2018, Article 7 shall be amended as follows:

 

	 	(a)	Section
    7.1(a) shall be deleted in its entirety and
    replaced with the following:

 

(a)
VBI shall supply
quantities of Licensed Product for use by Brii
Bio in the conduct of Clinical Trials to support an application for Marketing Approval in the Licensed Territory, either itself
or through a Third Party Manufacturer, subject to Section 7.2, in accordance with the terms and conditions set forth on Schedule
7.1(a) hereto, including the deliverables, cost allocation and timeframes set forth therein. For the avoidance of doubt, VBI shall
not be required to develop formulation processes for the manufacture of any Licensed Product other than VBI-2601 pursuant to this
Section 7.1(a) and any such formulation processes shall be developed by the Parties pursuant to the terms of the Development Plan.

 

	 	(b)	Section
    7.2(a) shall be deleted in its entirety and
    replaced with the following:

 

(a)
At any time prior to
the initiation of the first Phase III Clinical Trial (subject to Brii Bio’s ability to initiate an earlier transfer of Manufacturing
Technology as set forth in Schedule 7.1(a) in the event that VBI is delayed by more than six (6) months in meeting its final deliverable
obligations set forth therein) for the Licensed Product to support an application for Marketing Approval in the Licensed Territory,
Brii Bio may elect to have VBI transfer manufacturing responsibility for clinical supply and commercial supply to a Third Party
manufacturer either in the VBI Territory or the Licensed Territory (to the extent permitted by Applicable Law) (the “Third
Party Manufacturer”); provided that, VBI shall have no obligation to commence such transfer until after the Collaboration
Clinical Trial has been initiated. Once Brii Bio has elected to have VBI initiate such transfer, then VBI will use Commercially
Reasonable Efforts to effect a transfer of the Manufacturing Technology in accordance with the requirements set forth in this
Section 7.2(a), including the timeframes set forth in the foregoing sentence. The Parties shall mutually agree upon such Third
Party Manufacturer through the JSC, provided that the selection of such Third Party Manufacturer shall be subject to Brii Bio’s
final-decision making authority in accordance with Section 4.4(a). Once such selection has been made, the Parties shall enter
into a three (3)-party Supply Agreement with such Third Party Manufacturer for commercial supply of Licensed Products solely to
Brii Bio; provided that, VBI’s rights under such Third Party Manufacturer supply agreement shall be limited to ensuring
that such Third Party Manufacturer (i) maintains the confidentiality of VBI’s Confidential Information, including any information
related to the VBI Technology, (ii) complies with VBI’s obligations under the Ferring License, and (iii) complies with applicable
Licensed Product specifications and Applicable Laws. VBI shall use Commercially Reasonable Efforts to fully enable such Third
Party Manufacturer to manufacture Licensed Products, including through the technology transfer requirements set forth in Section
7.2(b) below.

 

    	3

    	 

    

 

 

5.
Amendment to Article 11.
Effective as of December 4, 2018, Article 11 of the Collaboration Agreement shall be amended as follows:

 

	 	a)	Section
    11.1 shall be deleted in its entirety and
    replaced with the following:

 

11.1
Confidential Information.
Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties
agree that the receiving Party (the “Receiving Party”) shall keep confidential and shall not publish or otherwise
disclose or use for any purpose other than as provided for in this Agreement any confidential or proprietary information and materials,
patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or otherwise) which is disclosed to it
or to its Affiliates by the other Party or its Affiliates (the “Disclosing Party”) including, but not limited to,
all Know How, Inventions and any other technical, regulatory or business information of whatever nature (collectively, “Confidential
Information”). For purposes of this Agreement, (a) all VBI Know-How shall be Confidential Information of VBI and (b) all
Brii Bio Know-How shall be Confidential Information of Brii Bio.

 

	 	(a)	Section 11.2 shall be deleted in its entirety and replaced with the following:

 

11.2
Exceptions. Notwithstanding
Section 11.1 above, the obligations of confidentiality and non-use shall not apply to Confidential Information that, in each case
as demonstrated by competent evidence:

 

(a)
was already known
to the Receiving Party or any of its Affiliates,
other than under an obligation of confidentiality, at the time of disclosure;

 

(b)
was generally available to the public or
was otherwise part of the public domain at the time of its disclosure to the Receiving
Party or any of its Affiliates;

 

(c)
became generally available to the public
or otherwise part of the public domain after its disclosure by the Disclosing Party or one of its Affiliates and other than through
any act or omission of the Receiving Party or any of its Affiliates in breach of this Agreement;

 

(d)
was subsequently lawfully disclosed to the
Receiving Party or any of its Affiliates by a Person other than the Disclosing Party, and who, to the best knowledge of the Receiving
Party, did not directly or indirectly receive such information directly or indirectly
from the Disclosing Party or one of its Affiliates under an obligation of confidence; or

 

(e)
was independently developed by the Receiving
Party or its Affiliate without use of or reference to any information or materials disclosed by the Disclosing Party or one of
its Affiliates.

 

	 	(c)	Section
    11.3 shall be deleted in its entirety and replaced with the following:

 

11.3
Permitted Disclosures. Notwithstanding the provisions of Section 11.1, each Party may disclose Confidential Information belonging
to the other Party or its Affiliates as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably
necessary in the following instances:

 

(a)
filing or prosecuting Patents as permitted
by this Agreement;

 

(b)
prosecuting or defending
litigation as permitted by this Agreement;

 

    	4

    	 

    

 

(c)
submission to a Regulatory Authority in connection
with a Marketing Approval of a Licensed Product;

 

(d)
complying with applicable court orders, Applicable
Law or governmental regulations including the requirements of any securities exchange;

 

(e)
to those of its employees, Affiliates, contractors
or agents who have a need to know such Confidential Information in order to enable the Receiving Party to carry out its obligations
pursuant to this Agreement provided that such persons are subject to obligations of confidentiality and non-use at least equivalent
in scope to the obligations set forth in this Article 11;

 

(f) to
existing or potential acquirers or merger candidates; investment bankers; existing or potential investors, venture capital firms
or other financial institutions or investors for purposes of obtaining financing, each of
whom prior to disclosure must be bound by obligations of confidentiality and non-use at least equivalent in scope to those
set forth in this Article 11; and advisors; provided, however, that neither Party shall make such disclosure to a competitor of
the other Party, without obtaining the Disclosing Party’s prior consent in writing; and provided further, that each Party
will remain responsible for any failure by any of the foregoing individuals to treat such Confidential Information as required
under Section 11.1 as if such individuals were parties directly bound to the requirements of this Article 11.

 

Notwithstanding
the foregoing, in the event a Party is required to make a disclosure of the other Party’s Confidential Information (including
information belonging to such Party’s Affiliates), it shall, except where impracticable, give reasonable advance notice
to the other Party of such disclosure and use efforts to secure confidential treatment of such information at least as diligent
as such Party would use to protect its own confidential information, but in no event less than reasonable efforts; provided, that
any Confidential Information so disclosed shall still be subject to the restrictions on use set forth in this Article 11. In any
event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder.

 

    	5

    	 

    

 

6.
Amendment to Article 14.
Effective as of December 4, 2018, Article 14 of the Collaboration Agreement shall be amended as follows:

 

	 	(a)	Section
    14.1 shall be deleted in its entirety and replaced with the following:

 

14.1
Indemnification of VBI. Brii Bio shall indemnify and hold harmless VBI and its Affiliates, and its and their directors, officers,
employees and agents of such entities (the “VBI Indemnitees”) from and against any and all losses, liabilities,
damages, penalties, fines, costs and expenses (including reasonable attorneys’ fees and other expenses of litigation) (“Losses”)
from any claims, actions, suits or proceedings brought by a Third Party (a “Third Party Claims”) incurred by
any VBI Indemnitee, arising from, or occurring as a result of: (a) the development, manufacture, use, handling, storage, sale
or other disposition of Licensed Product by Brii Bio or its Affiliates or Sublicensees in the Licensed Territory (which, for greater
certainty, includes Clinical Trials conducted by Brii outside the Licensed Territory for the purpose of supporting an application
for Market Approval in the Licensed Territory); (b) gross negligence or willful misconduct by or on behalf of Brii Bio or its
Affiliates in performing any activities in connection with this Agreement; and (c) any material breach of any representations,
warranties or covenants by Brii Bio under this Agreement; except, in each case ((a) – (c)), to the extent such Third Party
Claims fall within the scope of the indemnification obligations of VBI set forth in Section 14.2.

 

	 	(b)	Section
    14.4 shall be deleted in its entirety and replaced with the following:

 

14.4
Insurance. Each Party, at its own expense, shall maintain product liability and other appropriate insurance (including
D&O insurance) in an amount consistent with industry standards, for a company in a similar position to such Party, during
the Term, which shall include, but not be limited to ten million Dollars ($10,000,000). Each Party shall ensure that its product
liability insurance policy affords the other Party (and, in the case of VBI, its subsidiary SciVac Limited) the status of additional
insured under such policy. Each Party shall provide the other Party with written notice at least thirty (30) days prior to any
cancellation, nonrenewal or material change in the insurance described above. Each Party shall provide a certificate of insurance
evidencing such coverage to the other Party upon request. If a Party’s insurance certificate for product liability insurance
names any additional insured, then such Party shall ensure that the other Party is identified as an additional insured on such
certificate. Each Party shall provide a certificate of insurance evidencing its D&O insurance annually. It is understood that
such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification
obligations under this Article 14.

 

7.
Amendment to Article 15.
Effective as of December 4, 2018, Article 15 shall be amended as follows:

 

	 	(a)	Section
    15.3 shall be deleted in its entirety and replaced with the following:

 

15.3
Other Brii Bio Termination Rights.

 

(a)
Voluntary Termination. Brii
Bio shall have the right in its sole and absolute discretion, to terminate this Agreement, either with respect to a Region or
in its entirety, upon one hundred and eighty (180) days prior written notice to VBI for convenience, without cause, and for any
or no reason.

 

    	6

    	 

    

 

(b)
Termination for Safety Reasons. Brii
Bio may terminate this Agreement at any time during the Term immediately upon providing written notice to VBI if a Data and Safety
Monitoring Board or any Regulatory Authority in the Licensed Territory or in a country where a Clinical Trial is being conducted
by Brii for the purpose of supporting an application for Market Approval in the Licensed Territory imposes a clinical hold on
any Clinical Trial for a Licensed Product for six (6) consecutive months.

 

(b)
Section 15.6 shall be deleted in its entirety and replaced with the following:

 

15.6
Clinical Trials Upon Termination. In the event there are any on-going Clinical Trials of the Licensed Product in the Field
for the purpose of supporting an application for Marketing Approval in the Licensed Territory as of the date of termination hereof,
the Parties shall negotiate in good faith and adopt a plan to wind-down such Clinical Trials in an orderly fashion or,
at VBI’s election, promptly transition such development activities to VBI or its designee, with due regard for patient safety
and the rights of any subjects that are participants in any Clinical Trials and take
any actions it deems reasonably necessary or appropriate to avoid any human health or safety problems and in compliance with all
Applicable Laws.

 

8.
Amendment to Schedule 7.1(a). As
of the Effective Date, Schedule 7.1(a) shall be amended by the deletion of the second
bullet point and its replacement with the following:

 

	 	●	VBI
    will provide clinical supply at VBI’s cost and expense for GMP Batch 0, GMP Batch 1, GMP Batch 2 and the Tox Study in
    support of 50mcg dose. Such clinical supply shall be transferred to Brii Bio in accordance with a mutually agreed upon material
    transfer agreement which shall be entered into by the Parties no later than 30 days prior to the first contemplated transfer
    of such clinical supply. VBI shall use Commercially Reasonable Efforts to provide additional quantities of clinical supply
    for Clinical Trials to support an application for Marketing Approval in the Licensed Territory to Brii Bio at VBI’s
    fully burdened manufacturing costs. Brii Bio will be responsible for any additional costs specifically related to the Brii
    Bio Adjuvant and required formulation for the Novel Composition.

 

9.
Collaboration Agreement to Remain in Full
Effect. Except as amended by this Agreement,
the Collaboration Agreement shall continue to be in full force and effect, without amendment, and is hereby ratified and
confirmed. The Collaboration Agreement shall henceforth be read and construed in conjunction with this Agreement.

 

10.
Further Assurances. Each
Party agrees to execute, acknowledge and deliver such further instruments, and to
perform all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

11.
Execution and Counterparts. This
Agreement may be executed in two (2) counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Executed signature pages of this Agreement may be scanned and delivered electronically
and such signatures shall be deemed to bind each Party hereto as if they were original signatures.

 

[Signature
Page Follows]

 

    	7

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed Agreement as of the Effective Date.

 

	 	VBI
    VACCINES INC.
	 	 	 
	 	By:	/s/
                                         J. Baxter

	 	Name:	J.R.
    BAXTER
	 	Title:	CEO

 

	 	BRII
    BIOSCIENCES LIMITED
	 	 	 
	 	By:	/s/
    Zhi Hong    
	 	Name:	Zhi
    Hong
	 	Title:	CEODocument

Exhibit 10.4

SEPARATION AND RELEASE AGREEMENT

This Separation and Release Agreement (the “Agreement”), dated as of March 30, 2021, is entered into by and between Thomas J. Barrack, Jr. (“Executive”) and Colony Capital, Inc. (f/k/a Colony Financial, Inc. “CLNY”, and together with its subsidiaries, the “Employer”). Capitalized terms used but not defined herein shall have the meanings specified in the Employment Agreement by and between Employer and Executive, dated as of December 23, 2014, as amended (the “Employment Agreement”).

1.    SEPARATION DATE.  Executive and the Employer each acknowledges and agrees that the termination of Executive’s employment with Employer, shall be effective as of April 1, 2021 (the “Separation Date”). Executive acknowledges and agrees that, effective as of Separation Date and pursuant to Section 4(g) of the Employment Agreement, Executive will resign from any and all positions Executive then holds as a director, officer or otherwise, with the Employer and its managed entities, except Executive shall not resign from his position as a member of the Board of Directors of CLNY.  Executive agrees to execute any and all further documents necessary or appropriate to further memorialize any or all of such resignations.

2.    SEVERANCE PAYMENTS AND BENEFITS. Executive and Employer acknowledge and agree that the payments and benefits set forth in this Agreement (the “Post-Termination Benefits”), are the sole payments and benefits payable to Executive in connection with his termination of employment. Executive acknowledges and agrees that the Post-Termination Benefits provided for in Section 2(b) shall be subject to Executive executing the general release of claims attached hereto as Annex A (the “Supplemental Release”) within twenty-one (21) days following the Separation Date pursuant to the terms hereof, and the applicable seven (7) calendar day revocation period expiring without revocation (the “Supplemental Release Condition”). Executive acknowledges and agrees Executive is not entitled to receive an Unpaid Bonus as Executive’s 2020 cash bonus was paid on March 3, 2021.

(a)    Executive shall be entitled to receive the Accrued Benefits at the time or times provided for in Section 4(a)(i) of the Employment Agreement.

(b)    Subject to the occurrence of the Supplemental Release Condition, the following amounts shall be paid or provided to Executive:

(i)    A lump sum cash payment in the amount of $21,411,978, payable on the first regularly scheduled payroll date following the occurrence of the Supplemental Release Condition;

(ii)    The Pro-Rated Bonus: $1,062,500, payable on the first regularly scheduled payroll date following the occurrence of the Supplemental Release Condition;

1

(iii)    Continued coverage for Executive and Executive’s eligible dependents for the remainder of Executive’s life at the expense of the Company under medical, dental and vision programs of Employer that are the same or substantially similar to those programs in which Executive and Executive’s eligible dependents participated immediately prior to the Separation Date (the “Group Health Benefits”); provided that (x) unless otherwise agreed by Executive, all such Group Health Benefits coverages shall be provided under insured plans or arrangements, and (y) if the Company determines in good faith that continuation of Group Health Benefits coverage (1) would adversely affect the tax status of the plan(s) pursuant to which the Group Health Benefits are provided or (2) result in taxability of benefits or penalties on the Company under applicable law (including without limitation, pursuant to Section 2716 of the Public Health Service Act, the Patient Protection and Affordable Care Act, or Section 4980D of the Code), then in either case the Company may cease providing continuation of the Group Health Benefits coverage and instead provide the Executive with monthly cash payments in an amount that, after reduction for applicable taxes (assuming the Executive pays taxes at the highest marginal rates in the applicable jurisdictions), is equal to the cost of providing the continuing Group Health Benefits coverage referenced above;

(iv)    (A) All equity or equity-based awards actually issued to Executive by the Company prior to the Separation Date that vest solely based on Executive’s continued employment shall be fully vested (“Time-Based Awards”) and (B) all equity or equity-based awards actually issued to Executive by the Company prior to the Separation Date that vest based in whole or in part on the achievement of specified performance goals or metrics (“Performance Awards”) shall remain outstanding and continue to vest based on the level of actual achievement of such performance goals or metrics as provided for in the Performance Awards, it being acknowledged and agreed by the Company that (1) any determination permitted or required to be made by the Compensation Committee (the “Compensation Committee”) of the Board of Directors of the Company (the “Board”) or the Board with respect to the Performance Awards (including the achievement or failure to achieve the performance goals or metrics provided for therein) (A) will not treat Executive less favorably than the other senior executive officers of the Company and (B) will not have the effect of amending or modifying the terms of any Performance Award if such amendment or modification would result in a reduction or delay in the vesting of the Performance Awards and (2) if the Compensation Committee or Board were to waive or modify the performance goals or metrics attributable to performance awards granted to other senior executive officers of the Company on dates on which the Performance Awards were granted to Executive that results in an increase or acceleration of the vesting of such other performance awards, such waiver or modification shall also apply to the Performance Awards granted to Executive.  For clarification, and subject to the immediately preceding sentence, (1) vesting of the Performance Awards shall be solely based on achievement of the performance goals or metrics applicable thereto and shall not require continuation of employment or services to the Company and (2) vesting of the Time-Based Awards and the Performance Awards shall be final and not be subject to forfeiture, repurchase, so-called claw back rights or similar provisions.  A schedule of all Time-Based Awards and Performance Awards is set forth in the chart included on Exhibit B hereto;

(v)    Notwithstanding any provision in any award or partnership or similar agreement (including any provisions providing for vesting, forfeiture, performance conditions, repurchase, so-called claw back rights or similar provisions), all Fund Incentives issued to Executive on or prior to the Separation Date shall be fully vested.  In addition (A) 

2

Executive shall be issued vested Fund Incentives (the “DCP II Fund Incentive”) with respect to Digital Colony Partners II, L.P., with a sharing percentage of 5%, provided, that such DCP II Fund Incentive shall be issued at the same time as such incentives are issued to other recipients in the ordinary course of business and (B) at the sole discretion of the CEO of the Company, Executive shall be eligible to be issued Fund Incentives in other Company products for which Executive has assisted in deal sourcing or fundraising. A schedule of Fund Incentives other than the DCP II Fund Incentive is set forth in the chart included on Exhibit B hereto; and

(vi)    Executive is hereby released from any and all lock-up provisions on the Company shares (including the shares issued to Executive in March 2020, which Company shares were issued in lieu of Executive’s 2019 cash bonus) imposed on Executive or his Affiliates (other than Company policies applicable to Directors generally) .

3.    EXECUTIVE’S GENERAL RELEASE OF CLAIMS.

(a)    Waiver and Release. For and in consideration of continued employment with Employer through the Separation Date, the benefits provided for in this Separation and Release Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Executive, on behalf of himself and his heirs, executors, administrators and assigns, forever waives, releases and discharges Employer, its officers, directors, owners, shareholders and agents (collectively referred to herein as, the “Employer Group”), and each of its and their respective officers, directors, shareholders, members, managers, employees, agents, servants, accountants, attorneys, heirs, beneficiaries, successors and assigns (together with the Employer Group, the “Employer Released Parties”), from any and all claims, demands, causes of actions, fees, damages, liabilities and expenses (including attorneys’ fees) of any kind whatsoever, whether known or unknown, that Executive has ever had or might have against the Employer Released Parties that directly or indirectly arise out of, relate to, or are connected with, Executive’s services to, or employment by the Company, including, but not limited to (i) any claims under Title VII of the Civil Rights Act, as amended, the Americans with Disabilities Act, as amended, the Family and Medical Leave Act, as amended, the Fair Labor Standards Act, as amended, the Equal Pay Act, as amended, the Employee Retirement Income Security Act, as amended (with respect to unvested benefits), the Civil Rights Act of 1991, as amended, Section 1981 of Title 42 of the United States Code, the Sarbanes-Oxley Act of 2002, as amended, the Worker Adjustment and Retraining Notification Act, as amended, the Uniform Services Employment and Reemployment Rights Act, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, and/or any other federal, state or local law (statutory, regulatory or otherwise) that may be legally waived and released, and (ii) any tort and/or contract claims, including any claims of wrongful discharge, defamation, emotional distress, tortious interference with contract, invasion of privacy, nonphysical injury, personal injury or sickness or any other harm. Executive acknowledges that if the Equal Employment Opportunity Commission or any other administrative agency brings any charge or complaint on his behalf or for his benefit, the agreements in this Section 3 (this “Release”) bars Executive from receiving, and Executive hereby waives any right to, any monetary or other individual relief related to such a charge or complaint. This Release, however, excludes

3

(i) any claims made under state workers’ compensation or unemployment laws, and/or any claims that cannot be waived by law, (ii) claims with respect to the breach of any covenant (including any covenants under the Employment Agreement and this Separation and Release Agreement) to be performed by Employer after the date of this Release, (iii) any rights to indemnification or contribution or directors’ and officers’ liability insurance under the Employment Agreement, the Indemnification Agreement (as defined below), any operative documents of the Company or any applicable law, (iv) any claims as a holder of Company equity awards under the Company’s equity incentive plans or as a holder of Fund Incentives, (v) any claims for vested benefits under any employee benefit plan (excluding any severance plan and including claims under the Consolidated Omnibus Budget Reconciliation Act of 1985) or any claims that may arise after the date Executive signs the Release, (vi) any additional amounts or benefits due under any applicable plan, program, agreement or arrangement of Employer or any Managed Company (including continuing “tail” indemnification and directors and officers liability insurance for actions and inactions occurring while the Executive provided services for Employer and its affiliates and continued coverage for any actions or inactions by the Executive while providing cooperation under this Agreement), including any such plan, program, agreement or arrangement relating to equity or equity-based awards, (vii) the Post-Termination Benefits, and (viii) claims with respect to the breach of any covenant under the Tax Protection Agreement to which the Company and the Executive are parties.

(b)    Waiver of Unknown Claims; Section 1542.  Executive intends to fully waive and release all claims against Employer; therefore, he expressly understands and hereby agrees that this Release is intended to cover, and does cover, not only all known injuries, losses or damages, but any injuries, losses or damages that he does not now know about or anticipate, but that might later develop or be discovered, including the effects and consequences of those injuries, losses or damages. Executive expressly waives the benefits of and right to relief under California Civil Code Section 1542 (“Section 1542”), or any similar statute or comparable common law doctrine in any jurisdiction. Section 1542 provides:

Section 1542. (General Release-Claims Extinguished) A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

Executive understands and acknowledges the significance and consequences of this specific waiver of Section 1542 and, having had the opportunity to consult with legal counsel, hereby knowingly and voluntarily waives and relinquishes any rights and/or benefits which he may have thereunder. Without limiting the generality of the foregoing, Executive acknowledges that by accepting the benefits and payments offered in exchange for this Release, he assumes and waives the risks that the facts and the law may be other than he believes and that, after signing this Release, he may discover losses or claims that are released under this Release, but that are presently unknown to him, and he understands and agrees that this Release shall apply to any such losses or claims. 

4

4.    NO CLAIMS BY EXECUTIVE. Executive affirms and warrants that he has not filed, initiated or caused to be filed or initiated any claim, charge, suit, complaint, grievance, action or cause of action against Employer or any of the other Employer Released Parties.

5.    COVENANTS.  At such time that Executive is not a member of the Board of Directors of CLNY, Executive shall be the Chairman Emeritus of CLNY, with compensation for such position to be consistent with the compensation of CLNY’s independent directors.

6.    NO ASSIGNMENT OF CLAIMS.  Executive affirms and warrants that he has made no assignment of any right or interest in any claim which he may have against any of the Employer Released Parties.

7.    ADVICE OF COUNSEL. Executive acknowledges: (a) that he has been advised to consult with an attorney regarding this Agreement and the Release; (b) that he has, in fact, consulted with an attorney regarding this Agreement and the Release; (c) that he has carefully read and understands all of the provisions of this Agreement and the Release; and (d) that he is knowingly and voluntarily executing this Agreement and the Release.

8.    INSURANCE; INDEMNIFICATION. Following the Separation Date, Executive shall continue to be covered by such comprehensive directors’ and officers’ liability insurance and errors and omissions liability insurance as the Employer has established and maintained in respect of its directors and officers generally for actions and inactions occurring while the Executive provided services for Employer and its managed entities and continued coverage for any actions or inactions by the Executive while providing cooperation under the Employment Agreement, at Employer’s expense, and the Employer shall cause such insurance policies to be maintained in a manner reasonably acceptable to the Executive in accordance with the provisions of clause (vi) of the last sentence of Section 3(a) above. The Executive shall also be entitled to indemnification rights, benefits and related expense advances and reimbursements under applicable law and pursuant to the indemnification agreements previously entered into with Employer (the “Indemnification Agreement”) all of which shall remain in full force and effect in accordance with their terms.
9.    RESTRICTIVE COVENANTS.  The Company acknowledges and agrees that nothing in the Release, the Restrictive Covenant Agreement, the Supplemental Release or otherwise shall prohibit or impede Executive from communicating, cooperating or filing a complaint with any U.S. federal, state, or local governmental or law enforcement branch agency or entity (“Governmental Agency”) with respect to possible violations of any U.S. federal, state or local law or regulation or otherwise making disclosure to any Governmental Agency, in each case, that are protected under the whistleblower provisions of any such law or regulation to the extent such communications and/or disclosures are consistent with applicable law. In addition, Executive is hereby notified in accordance with the Defend Trade Secrets Act of 2016 (“DTSA”) that he will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document that is filed under seal in a lawsuit or other proceeding.

5

10.    COMMUNICATIONS. Employer and Executive shall cooperate in good faith regarding any public announcement of Executive’s separation from employment with Employer, and Employer shall consider any timely comments from Executive related to any such communications in good faith.

11.    FEES. Employer shall promptly pay or reimburse Executive for reasonable attorneys’ fees incurred by Executive in connection with the review, negotiation, drafting and execution of this Agreement and the Supplemental Release and any agreements related thereto,  subject to Executive providing Employer with reasonable documentation of such fees. Employer shall reimburse Executive for such fees within ten (10) business days following Executive’s submission to Employer of the documentation evidencing the fees.

12.    PUBLIC ANNOUNCEMENT.  The Company shall consult with Executive prior to issuing any press release or any written public statement with respect to this Agreement or Executive’s termination of employment and shall not issue any such press release or written public statement prior to review and approval by Executive, except that prior review and approval shall not be required if, in the reasonable judgment of the Company, prior review and approval would prevent the timely dissemination of such release or announcement in violation of any applicable Law.

13.    MISCELLANEOUS.  The provisions of this Agreement and the Supplemental Release are severable, and, if any part of this Agreement or the Supplemental Release is found to be unenforceable, the other paragraphs shall remain fully valid and enforceable.  This Agreement and the Supplemental Release shall be governed by the substantive laws of the State of California without reference to its conflict of laws principles.  This Agreement and the Supplemental Release set forth the entire agreement and understanding between the Employee and the Company.  The Company has made no promises to the Employee other than those herein.  Any dispute arising between the parties to this Agreement, including, but not limited to, any act which allegedly has or would violate any provisions of this Agreement or the Supplemental Release, and including, but not limited to, disputes pertaining to the formation, validity, interpretation, effect, or alleged breach of this Agreement or the Supplemental Release shall be submitted to mandatory and binding arbitration pursuant to the procedures set forth in the Employment Agreement.
[remainder of page intentionally left blank]

6

                
																		
		EXECUTIVE
			COLONY CAPITAL, INC.	
						
		 /s/ Thomas J. Barrack    			  /s/ Ronald M. Sanders         	
		 Thomas J. Barrack, Jr.			Name: Ronald M. Sanders	
					Title: Executive Vice President   	
						
						
						
						
						

[Signature Page to Separation and Release Agreement]

Annex A Supplemental Release
This Supplemental Release is entered into by and between Thomas J. Barrack, Jr. (“Executive”) and Colony Capital, Inc. (f/k/a Colony Financial, Inc. “CLNY”, and together with its subsidiaries, the “Employer”). Capitalized terms used but not defined herein shall have the meanings specified in the Separation and Release Agreement, dated as of March 30, 2021, by and between Employer and Executive (the “Separation Agreement”).

For and in consideration of the Post-Termination Benefits and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Executive agrees as follows:

1.    Waiver and Release. Executive, on behalf of himself and his heirs, executors, administrators and assigns, forever waives, releases and discharges Employer, its officers, directors, owners, shareholders and agents (collectively referred to herein as, the “Employer Group”), and each of its and their respective officers, directors, shareholders, members, managers, employees, agents, servants, accountants, attorneys, heirs, beneficiaries, successors and assigns (together with the Employer Group, the “Employer Released Parties”), from any and all claims, demands, causes of actions, fees, damages, liabilities and expenses (including attorneys’ fees) of any kind whatsoever, whether known or unknown, that Executive has ever had or might have against the Employer Released Parties that directly or indirectly arise out of, relate to, or are connected with, Executive’s services to, or employment by the Company, including, but not limited to (i) any claims under Title VII of the Civil Rights Act, as amended, the Americans with Disabilities Act, as amended, the Family and Medical Leave Act, as amended, the Fair Labor Standards Act, as amended, the Equal Pay Act, as amended, the Employee Retirement Income Security Act, as amended (with respect to unvested benefits), the Civil Rights Act of 1991, as amended, Section 1981 of Title 42 of the United States Code, the Sarbanes-Oxley Act of 2002, as amended, the Worker Adjustment and Retraining Notification Act, as amended, the Age Discrimination in Employment Act, as amended, the Uniform Services Employment and Reemployment Rights Act, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, and/or any other federal, state or local law (statutory, regulatory or otherwise) that may be legally waived and released, and (ii) any tort and/or contract claims, including any claims of wrongful discharge, defamation, emotional distress, tortious interference with contract, invasion of privacy, nonphysical injury, personal injury or sickness or any other harm. Executive acknowledges that if the Equal Employment Opportunity Commission or any other administrative agency brings any charge or complaint on his behalf or for his benefit, this Supplemental Release bars Executive from receiving, and Executive hereby waives any right to, any monetary or other individual relief related to such a charge or complaint. This Supplemental Release, however, excludes (i) any claims made under state workers’ compensation or unemployment laws, and/or any claims that cannot be waived by law, (ii) claims with respect to the breach of any covenant (including any covenant under the Employment Agreement or this Separation Agreement and Release) to be performed by Employer after the date of this Supplemental Release, (iii) any rights to indemnification or contribution or directors’ and officers’ liability insurance under the 
A-1

Employment Agreement, the Indemnification Agreement, any operative documents of the Company or any applicable law, (iv) any claims as a holder of Company equity awards under the Company’s equity incentive plans or as a holder of Fund Incentives, (v) any claims for vested benefits under any employee benefit plan (excluding any severance plan and including claims under the Consolidated Omnibus Budget Reconciliation Act of 1985) or any claims that may arise after the date Executive signs the Release, and (vi) any additional amounts or benefits due under any applicable plan, program, agreement or arrangement of Employer or any Managed Company (including continuing “tail” indemnification and directors and officers liability insurance for actions and inactions occurring while the Executive provided services for Employer and its affiliates and continued coverage for any actions or inactions by the Executive while providing cooperation under this Agreement), including any such plan, program, agreement or arrangement relating to equity or equity-based awards; (vii) the Post-Termination Benefits, and (viii) claims with respect to the breach of any covenant under the Tax Protection Agreement or Investment Agreement to which the Company and the Executive are parties. 

2.    Waiver of Unknown Claims; Section 1542. Executive intends to fully waive and release all claims against Employer; therefore, he expressly understands and hereby agrees that this Supplemental Release is intended to cover, and does cover, not only all known injuries, losses or damages, but any injuries, losses or damages that he does not now know about or anticipate, but that might later develop or be discovered, including the effects and consequences of those injuries, losses or damages. Executive expressly waives the benefits of and right to relief under California Civil Code Section 1542 (“Section 1542”), or any similar statute or comparable common law doctrine in any jurisdiction. Section 1542 provides:

Section 1542. (General Release-Claims Extinguished) A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

Executive understands and acknowledges the significance and consequences of this specific waiver of Section 1542 and, having had the opportunity to consult with legal counsel, hereby knowingly and voluntarily waives and relinquishes any rights and/or benefits which he may have thereunder. Without limiting the generality of the foregoing, Executive acknowledges that by accepting the benefits and payments offered in exchange for this Supplemental Release, he assumes and waives the risks that the facts and the law may be other than he believes and that, after signing this Supplemental Release, he may discover losses or claims that are released under this Supplemental Release, but that are presently unknown to him, and he understands and agrees that this Supplemental Release shall apply to any such losses or claims.

3.    Acknowledgement of ADEA Waiver. Without in any way limiting the scope of the foregoing general release of claims, Executive acknowledges that he is waiving and releasing any rights he may have under the Age Discrimination in Employment Act of 1967 (the “ADEA”) and that such waiver and release is knowing and voluntary. This waiver and release does not govern any rights or claims that might arise under the ADEA after the date this Supplemental 
A-2

Release is signed by Executive. Executive acknowledges that: (i) the consideration given for this Supplemental Release is in addition to anything of value to which Executive otherwise would be entitled to receive; (ii) he has been advised in writing to consult with an attorney of his choice 

prior to signing this Supplemental Release; (iii) he has been provided a full and ample opportunity to review this Supplemental Release, including a period of at least twenty-one (21) days within which to consider it (which will not be lengthened by any revisions or modifications); (iv) he has read and fully understands this Supplemental Release and has had the opportunity to discuss it with an attorney of his choice; (v) to the extent that Executive takes less than twenty-one (21) days to consider this Supplemental Release prior to execution, he acknowledges that he had sufficient time to consider this Supplemental Release with counsel and that he expressly, voluntarily and knowingly waives any additional time; and (vi) Executive is aware of his right to revoke this Supplemental Release at any time within the seven (7)-day period following the date on which he executes this Supplemental Release. Executive further understands that he shall relinquish any right he has to Post-Termination Benefits described in the Employment Agreement if he exercises his right to revoke this Supplemental Release. Notice of revocation must be made in writing and must be received by Ronald Sanders, General Counsel, Colony Capital, Inc., no later than 5:00
p.m. Pacific Time on the seventh (7th) calendar day immediately after the day on which Executive executes this Supplemental Release.

4.    Wages Fully Paid. Executive acknowledges and agrees that he has received payment in full for all salary and other wages, including without limitation any accrued, unused vacation or other similar benefits earned through the Separation Date other than the Post-Termination Payments.

5.    No Claims by Executive. Executive affirms and warrants that he has not filed, initiated or caused to be filed or initiated any claim, charge, suit, complaint, grievance, action or cause of action against Employer or any of the other Employer Released Parties.

6.    No Assignment of Claims. Executive affirms and warrants that he has made no assignment of any right or interest in any claim which he may have against any of the Employer Released Parties.

7.    Advice of Counsel.  Executive acknowledges: (a) that he has been advised to consult with an attorney regarding this Supplemental Release; (b) that he has, in fact, consulted with an attorney regarding this Supplemental Release; (c) that he has carefully read and understands all of the provisions of this Supplemental Release; and (d) that he is knowingly and voluntarily executing this Supplemental Release in consideration of the Post-Termination Benefits provided under the Employment Agreement and the Separation Agreement.

8.    Certain Covenants.  The Company acknowledges and agrees that nothing in the Release, the Restrictive Covenant Agreement, Supplemental Release or otherwise shall prohibit or impede Employee from communicating, cooperating or filing a complaint with any U.S. federal, state, or local governmental or law enforcement branch agency or entity (“Governmental Agency”) with respect to possible violations of any U.S. federal, state or local law or regulation 
A-3

or otherwise making disclosure to any Governmental Agency, in each case, that are protected under the whistleblower provisions of any such law or regulation to the extent such communications and/or disclosures are consistent with applicable law. In addition, Employee is hereby notified in accordance with the Defend Trade Secrets Act of 2016 (“DTSA”) that he will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document that is filed under seal in a lawsuit or other proceeding.

9.    Miscellaneous.  The provisions of this Supplemental Release are severable, and, if any part of this Supplemental Release is found to be unenforceable, the other paragraphs shall remain fully valid and enforceable.  This Supplemental Release shall be governed by the substantive laws of the State of California without reference to its conflict of laws principles.  This Supplemental Release, along with the Separation Agreement, sets forth the entire agreement and understanding between the Employee and the Company with respect to the subject matter hereof and thereof.  The Company has made no promises to the Employee other than those herein or in the Separation Agreement.  Any dispute arising between the parties to this Supplemental Release, including, but not limited to, any act which allegedly has or would violate any provisions of this Supplemental Release, and including, but not limited to, disputes pertaining to the formation, validity, interpretation, effect, or alleged breach of this Supplemental Release shall be submitted to mandatory and binding arbitration pursuant to the procedures set forth in the Employment Agreement.

[remainder of page intentionally left blank]
A-4

																		
		EXECUTIVE
			COLONY CAPITAL, INC.	
						
						
		 Thomas J. Barrack, Jr.			Name:	
		Date:                                           			Title:	
					Date:	
						
						
						
						

[Signature Page to Supplemental Release Agreement]

Annex B

Equity Awards and Fund Incentives
[Attached]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]